SCHEMBL311657

SCHEMBL311657

CC(C)(C)C1C[C@H](c2ccc(OCc3ccccc3)cc2)N(C(=O)O)[C@]1(C)C(N)=O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.46
TP53 P04637 1/20 0.44
PARP10 Q53GL7 1/20 0.43
AMPD2 Q01433 1/20 0.42
MMP13 P45452 1/20 0.41
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
SIRT1 Q96EB6 1/20 0.41
ADAM17 P78536 3/20 0.41
USP2 O75604 1/20 0.41
GLA P06280 1/20 0.41
HTT P42858 1/20 0.41
MAOB P27338 3/20 0.40
KDM1A O60341 2/20 0.40
MAOA P21397 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL483408 1.00 KCNH2 (0.46) KCNH2TP53PARP10AMPD2MMP13
SCHEMBL483795 0.88 KCNH2 (0.54) KCNH2PARP10OPRM1OPRD1MAOB
SCHEMBL310676 0.88 KCNH2 (0.54) KCNH2PARP10OPRM1OPRD1MAOB
SCHEMBL483784 0.85 KCNH2 (0.51) KCNH2MMP13ADAM17MAOB
SCHEMBL483568 0.79 KCNH2 (0.48) KCNH2TP53NPC1RAB9A
SCHEMBL2832438 0.78 KCNH2 (0.51) KCNH2TP53PARP10AMPD2OPRM1
SCHEMBL2831540 0.78 KCNH2 (0.51) KCNH2TP53PARP10AMPD2OPRM1
SCHEMBL840063 0.78 KCNH2 (0.48) KCNH2TP53PARP10AMPD2ADAM17
SCHEMBL841357 0.78 KCNH2 (0.48) KCNH2TP53PARP10AMPD2ADAM17
SCHEMBL310889 0.78 KCNH2 (0.48) KCNH2TP53PARP10AMPD2ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153623-B2 Compounds Convergence Pharmaceuticals Limited (GB) 2012-04-10 US disclosed
EP-1934176-B1 QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS GLAXO GROUP LTD (GB) 2012-02-01 EP disclosed
US-8093268-B2 Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) GLAXO GROUP LIMITED (GB) 2012-01-10 US disclosed
EP-2117562-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS GLAXO GROUP LTD (GB) 2011-10-26 EP disclosed
US-20100113521-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5-(5-TRIFLUOROMETHYL-TETRAZOL-1-YL-BENZYL)-(2S-PHENYLPIPERIDIN-3S-YL-) GLAXO GROUP LIMITED (GB) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113521-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5-(5-TRIFLUOROMETHYL-TETRAZOL-1-YL-BENZYL)-(2S-PHENYLPIPERIDIN-3S-YL-) KCNJ2, TRPV1, SCN5A KCNH2 11/4885TP53 4504/4885PARP10 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.